Bisolbruis

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisolbruis

Bisolbruis: Definition, Class, and Active Component

Bisolbruis is a pharmaceutical product whose single active substance is Acetylcysteine, also recognized chemically as N-acetylcysteine (NAC). This medication is classified primarily as a mucolytic agent and is included in the broader therapeutic category of expectorants. Pharmacologically, it is a sulfhydryl-containing compound with antioxidant capabilities, acting as a glutathione precursor. In this capacity, the substance provides a structural component that supports the body's natural cellular defenses.

As a distinct product within its category, Bisolbruis utilizes the Acetylcysteine molecule, which is a synthetic derivative of the natural amino acid L-cysteine. Its classification as a mucolytic reflects its direct chemical action on the physical structure of mucus.

Composition, Origin, and Effervescent Form

The product is supplied as a single-ingredient oral preparation in the form of an effervescent tablet, a delivery method focused on ease of oral administration compared to liquid solutions or standard capsules. This format is formulated to ensure rapid dissolution when mixed with water.

The use of Acetylcysteine for managing respiratory secretions is based on its pharmacological properties. Acetylcysteine exerts its effect by reducing the viscosity of tracheobronchial secretions. The core function of the medicine is to make thick mucus thinner and easier to clear from the respiratory tract.

The General Purpose of Acetylcysteine (NAC) Action

The primary purpose of Bisolbruis is to help relieve the difficulty associated with clearing thick, viscid secretions from the airways. It achieves this by directly cleaving the disulfide bonds that stabilize mucoprotein molecules, which reduces the stickiness of the mucus. Furthermore, by acting as a glutathione inducer, Acetylcysteine assists in maintaining the body's antioxidant capacity, offering a secondary physiological benefit that supports more comfortable respiration.

Regulatory References

  1. NIH Drug Record

What side effects are possible with Bisolbruis?

Official Safety Profile and Adverse Reactions

This section outlines the documented side effects and regulatory safety information for the active substance in Bisolbruis (Acetylcysteine), based strictly on official governmental health authority documents.

Serious Adverse Reactions

The official regulatory safety profile highlights the potential for anaphylactic shock and severe, potentially life-threatening allergic reactions (anaphylaxis). Additionally, very rare but serious skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported. Regulatory documents require immediate discontinuation of the medicine if any changes to the skin or mucous membranes are observed.

Common Adverse Reactions

Adverse events classified as common (≥ 1/100 to < 1/10) typically affect the digestive system, and may include nausea, vomiting, abdominal pain, diarrhea, and stomatitis. Other common effects include headache and fever.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by the body system affected (System-Organ Class) and the frequency of occurrence as defined by regulatory standards:

Frequency System-Organ Class Involved Examples of Adverse Reactions
Common Gastrointestinal Disorders Nausea, vomiting, diarrhea
Uncommon Immune System, Vascular, Skin Hypersensitivity reactions, hypotension, rash, tachycardia
Very Rare Immune System, Skin Anaphylactic shock, SJS/TEN

Safety Restrictions and Limitations

The medicine is formally contraindicated (should not be used) in individuals with known hypersensitivity to the active substance or excipients, and in infants under two years of age for mucolytic indications. Caution is required in patients with a history of asthma or peptic ulcers. The sodium content must also be considered for patients following a controlled-sodium diet.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdosage of Acetylcysteine (the active component of Bisolbruis) is primarily characterized by documented gastrointestinal effects. These acute manifestations, as listed in regulatory documents, include Nausea, Vomiting, Diarrhea, and Abdominal pain.

While the oral pharmaceutical form is generally non-toxic in typical mucolytic dose ranges, regulatory guidance recognizes that massive acute overdosage may lead to severe, life-threatening systemic outcomes. These severe outcomes, reported in official labeling, include Hypotension, Bronchospasm, Respiratory failure, and anaphylactoid reactions that have resulted in fatal events.

Required Emergency Actions

The official guidance from health authorities mandates immediate action upon the suspicion of overdosage:

  • Stop the administration of Bisolbruis immediately.
  • Seek immediate medical attention or contact a poison control center or emergency room at once.
  • Emergency services must be contacted immediately if the individual has collapsed, has trouble breathing, or has a seizure.

Management Context

The management strategy officially defined for Acetylcysteine overdose is symptomatic and supportive treatment. The regulatory information states that no specific antidote is known for this type of overdosage. Clinical management involves supportive measures, including monitoring of vital functions.

Therapeutic Uses of Bisolbruis

What Bisolbruis Treats: Main Uses and Benefits

Bisolbruis (Acetylcysteine) is used for the symptomatic management of respiratory conditions characterized by abnormal, viscid, or inspissated mucous secretions. This medication is applied in addressing symptoms related to impaired mucus clearance that can be present in both acute and chronic respiratory disorders.

The primary objective is to ease the symptoms related to tenacious secretions, assisting with the management of impaired mucus clearance. This therapeutic support is relevant across various conditions presenting with acute episodes, such as bronchitis and tracheobronchitis, as well as chronic disorders like COPD and bronchiectasis. It is also applied in specific clinical scenarios, including post-operative chest care and tracheostomy management, where the retention of thick mucus may pose a clinical challenge.

“This medication is used in situations involving certain distressing symptoms where additional symptomatic support is needed to address the difficulty of coughing up thick phlegm.”


Quick Fact: Symptomatic Support for Thick Chest Congestion

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Regulatory documentation defines strict patient eligibility rules for Bisolbruis (Acetylcysteine). The medicine is officially used by adults and adolescents (typically from 14 years of age for the 600 mg strength) who experience conditions associated with thick respiratory secretions.

Use is absolutely contraindicated in the following populations:

  • Children younger than two years of age, due to the physiological risk of airway obstruction caused by mucolytics.
  • Patients with known hypersensitivity or allergy to acetylcysteine or any excipient in the formulation.
  • Individuals with active peptic ulceration.

Restrictions and Conditional Use

Bisolbruis is officially subject to restrictions for several populations, requiring special caution:

  • Bronchial Asthma: Caution is required due to the documented risk of bronchospasm.
  • History of Peptic Ulcer: Conditional use is required, especially when combined with other gastric irritants.
  • Impaired Organ Function: Caution is advised for patients with renal or hepatic impairment, as reduced clearance may occur.
  • Pregnancy and Lactation: Use is generally not recommended because the safety profile has not been fully established in pregnant or breastfeeding women. Use is only permitted following a strict clinical assessment of the benefit-risk ratio.
  • Reduced Cough Reflex: Caution is advised in patients with a limited ability to cough, due to the risk of increased, uncleared bronchial secretions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Acetylcysteine (Bisolbruis) based on pharmacodynamic effects, chemical constraints, and absorption factors.

Pharmacodynamic and Chemical Interaction Constraints

Interacting Substance/Class Regulatory Outcome/Restriction
Antitussive Drugs (Cough Suppressants) Co-administration is not recommended. This pharmacodynamic conflict may lead to a build-up of liquefied bronchial secretions by suppressing the cough reflex, hindering clearance.
Nitroglycerin (Nitric Oxide Donors) Acetylcysteine may potentiate the vasodilatory effects, which can result in significant hypotension and headache. Use requires caution and monitoring.
Oral Antibiotics (e.g., Cephalosporins) Doses must be separated in time. Oral antibiotics should be administered at least two hours before or two hours after Acetylcysteine to manage potential in vitro inactivation.
Activated Charcoal Can reduce the therapeutic effect of Acetylcysteine due to the mechanism of adsorption, which decreases drug exposure.
Carbamazepine Concomitant use has been reported to result in sub-therapeutic plasma levels of carbamazepine.

This information strictly details constraints defined in official government drug labels. No dedicated drug-drug interaction studies have been consistently conducted for pharmacokinetic parameters such as CYP enzymes. Furthermore, pharmacokinetic data notes that severe hepatic impairment increases the elimination half-life and decreases the overall clearance of Acetylcysteine.

Mechanism of Action

The mechanism of action for Acetylcysteine (Bisolbruis) involves a dual action: direct modification of mucus structure and indirect modulation of the cellular redox state.

Direct Chemical Mechanism: Reducing Mucus Viscosity

The primary action involves the direct chemical reduction of highly viscous mucus. The free sulfhydryl group ( -SH) of Acetylcysteine directly cleaves the strong disulfide bonds ( S-S) that cross-link the large mucoprotein (mucin) polymers . This depolymerization results in a reduction in the viscosity and elasticity of the tracheobronchial secretions, a physical change that facilitates the function of the mucociliary clearance pathway.

Indirect Mechanism: Modulating Cellular Redox State

A complementary action involves Acetylcysteine serving as a precursor to L-cysteine, the building block required for the synthesis of glutathione ( GSH), a critical intracellular antioxidant. The replenished GSH stores enhance the cellular capacity to neutralize Reactive Oxygen Species (ROS), thereby modulating oxidative stress. This process indirectly modulates inflammation-related pathways, influencing the cellular response to oxidative challenge within the respiratory epithelium.

Dosage and Administration Information

Administration Scope

Instruction Category Guideline
Route of Administration Oral route only, consumed as an aqueous solution.
Dosing Schedule (Adults) One 600 mg effervescent tablet daily. A dose of 300 mg twice daily is also utilized in specific applications.
Timing in Relation to Meals Usually taken after food.
Preparation Requirements The tablet must be fully dissolved in half a glass of water immediately before consumption. It must not be swallowed whole.
Age-Group Rules Use is contraindicated in children under 2 years of age. The 600 mg strength is typically reserved for adults and adolescents from 14 years of age due to the high active substance content.
Missed-Dose Rules If a dose is forgotten and it is near the time for the next scheduled dose, the missed dose is typically skipped to avoid taking a double dose.
Special Procedural Conditions For individuals with a reduced cough reflex, the dose is often taken in the mornings. The tablet is not to be dissolved or mixed with other medicinal products, particularly antibiotics.

Instruction Classifications (High-Level)

Classification Detail
Administration Method Type Oral solution.
Frequency Pattern Once daily (for 600 mg dose).
General Framework Standardized clinical profile.
Use-Context Constraints Short-term use, generally not to exceed 14 days without further medical evaluation.

Resulting Procedural Structure

Step Sequence:

  • Dissolve one 600 mg tablet in approximately half a glass of water.
  • Consume the resulting oral solution immediately, ideally after food.
  • Follow the schedule of one dose per day, limiting the course to two weeks unless otherwise advised.

These instructions establish the method of administration via a freshly prepared oral solution, the 600 mg once-daily dosage, and the temporal and duration limits for the medication's use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bisolbruis

Research on Chronic Respiratory Conditions (COPD and Bronchitis)

Research evaluated Acetylcysteine (the active ingredient in Bisolbruis) in chronic respiratory conditions like Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis and primarily relied on Randomized Controlled Trials (RCTs) and analyses that combine the findings of multiple trials (meta-analyses). These studies included adults diagnosed with these conditions, particularly those who experience ongoing problems with thick mucus production.

Researchers monitored outcomes related to the overall stability of the condition, such as the frequency and duration of disease exacerbations (or flare-ups), over long periods. Findings across these trials have been mixed. Some research described patterns of lower recorded exacerbation frequencies over time, particularly in certain study designs or populations, while other large trials conducted in different groups reported no significant difference in exacerbation rates or functional measures when compared to placebo. This variability across studies means the certainty of outcomes in all patient groups remains low.

Research on Acute Symptoms and Impaired Mucus Clearance

Research has examined Bisolbruis for short-term and acute respiratory symptoms, such as during episodes of bronchitis or in specific clinical situations like post-operative care. Studies were designed to investigate the compound's fundamental action, which is the chemical interaction with the sticky structure of thick, viscid mucus.

Evidence related to this indication is largely based on the product’s well-established chemical properties, supported by clinical trials that primarily measured outcomes related to physical discomfort, such as sputum viscosity and the ease of expectoration. However, the high-quality, large-scale RCTs specifically comparing the symptomatic support of Bisolbruis against placebo for acute illnesses are more limited than those for chronic disease management. Research describes that the main rationale for this use is the established physical thinning action on secretions; studies were designed to evaluate the resulting effect on clearance.

What Is Still Uncertain About the Research for Bisolbruis

Despite decades of research, data are still emerging, and several aspects about the evidence for Bisolbruis remain uncertain. The evidence quality varies across studies, and there is considerable heterogeneity in the results. Specifically, findings were mixed regarding the compound's effect on objective measures of lung function (PFTs), making it difficult to fully understand the compound’s long-term influence beyond the short-term outcomes measured. Additionally, comparative evidence is lacking in high-quality trials that directly compare Acetylcysteine against other mucolytic or respiratory therapies for its main indications.

Key Studies & References

  1. NIH DailyMed Drug Record: Acetylcysteine (Inhalation Solution) - General Pharmacological Information
  2. NIH DailyMed Drug Label: Acetylcysteine - Symptomatic Management and Indications

Frequently Asked Questions (FAQ)

Common questions about Bisolbruis (FAQ)


Q: How quickly can I expect Bisolbruis to start working?

Information from pharmacokinetic studies shows that the active ingredient in Bisolbruis is absorbed into the bloodstream after being taken orally. The concentration of the active ingredient typically reaches its highest level approximately one to two hours following administration.

Q: Is there a maximum number of days Bisolbruis should be used?

According to the official product information, the use of this medicine is intended to be short-term. Regulatory constraints state the course of use is generally limited to a maximum duration of 14 days unless further evaluation is performed by a healthcare professional.

Q: Can Bisolbruis be taken if I have asthma or breathing issues?

Regulatory documents advise that caution is required for patients who have a history of bronchial asthma. This caution is due to the documented risk of bronchospasm, which is a sudden tightening of the airways.

Q: Does Bisolbruis interact with blood pressure medication?

The official interaction profile notes that using the active ingredient with Nitroglycerin or other nitric oxide donors may increase their effect of widening blood vessels. This effect can result in hypotension (low blood pressure) and headache, and therefore requires caution.

Q: Can I take Bisolbruis if I am already taking paracetamol or ibuprofen?

Official drug interaction sections do not list a specific warning for use with paracetamol or ibuprofen. Patients with heart or kidney conditions may need to consider the product's sodium content, as described in official documents.

Q: Can elderly patients use Bisolbruis safely?

Official information advises caution for individuals with a reduced ability to cough. For patients whose cough reflex is limited, official documents note that administration in the mornings is suggested.

Q: Will Bisolbruis make me feel drowsy or tired?

Drowsiness or fatigue are not listed as common or uncommon side effects in the official safety profiles for this medicine. Some regulatory data does note that dizziness has been reported as a known clinical effect.

Q: Is Bisolbruis safe for someone who has previously had stomach ulcers?

The medicine is contraindicated (should not be used) in individuals who have active peptic ulceration. Caution is required for patients who only have a history of stomach ulcers.

Q: Does Bisolbruis contain codeine?

The medicine's single active substance is Acetylcysteine, which is classified as a mucolytic agent that thins mucus. Bisolbruis does not contain codeine.

Q: Why does the packaging say Bisolbruis is not for children under 12?

Official documentation contraindicates the use of the active ingredient in children under two years of age. The 600 mg strength of Bisolbruis is typically reserved for adults and adolescents from 14 years due to the high amount of active substance.

Q: Are there any common food or drink items that should be avoided when taking Bisolbruis?

The official instructions for administration state that the medicine should be taken after food. There are no specific common food or drink items listed in regulatory documents that must be avoided when taking Bisolbruis.

Q: Is it normal to notice a specific taste when taking Bisolbruis?

Bisolbruis is formulated as an effervescent tablet that must be dissolved in water. The active ingredient, Acetylcysteine, is a sulfur-containing compound which has a characteristic, slight sulfur-like taste and odor.

Q: Can Bisolbruis affect my ability to drive or operate machinery?

The official safety profile does not include a specific warning regarding driving ability. However, because side effects like dizziness (uncommon) or hypotension have been reported, the potential for these effects means that an individual's ability to drive or use machinery could be affected.

Q: Why do some people say they use Bisolbruis for a chest cold?

The medicine is officially indicated for conditions associated with the presence of thick respiratory secretions (mucus) in the airways. These symptoms are commonly experienced by individuals who are dealing with a 'chest cold.'

Q: Is there any research that explains how Bisolbruis helps with mucus?

Yes, research was designed to investigate the compound's fundamental action, which is the direct chemical interaction with the sticky structure of thick, viscid mucus. Studies confirm its established physical thinning action on these secretions.

Q: Is Bisolbruis considered a mucolytic or an expectorant?

Official classification states that Bisolbruis is primarily considered a mucolytic agent, meaning it thins mucus. It is also included in the broader therapeutic category of expectorants, which generally help bring up phlegm.

Q: Why do official documents mention Bisolbruis should be used with caution in patients with liver problems?

Caution is advised for patients with severe hepatic impairment (liver problems) due to official pharmacokinetic data. This data notes that reduced liver function increases the elimination half-life and decreases the overall clearance of Acetylcysteine in the body.

Q: Is Bisolbruis tested on specific age groups in clinical trials?

Research reviewed for chronic respiratory conditions (like COPD and chronic bronchitis) primarily involved adults diagnosed with these specific conditions.

Q: What is the difference between Bisolbruis and other common over-the-counter cough remedies?

Bisolbruis is specifically classified as a mucolytic agent that works to chemically thin thick mucus. This is a distinct pharmacological action compared to cough suppressants or other common remedies that may address only the cough reflex or fever.

Q: Is Bisolbruis considered habit-forming?

Official regulatory safety documents for this medicine do not include warnings or statements related to dependence, abuse potential, or the medication being habit-forming.

Q: Does taking Bisolbruis affect the results of any common medical tests?

The active ingredient can interfere with certain specific laboratory tests. This includes some glucose meters (which may show falsely high results) and specific biochemistry assays from particular manufacturers (which may show falsely low results for cholesterol or uric acid).

Q: Are there specific storage instructions for Bisolbruis tablets?

Regulatory requirements describe that the tablets should be protected from moisture and stored in the original packaging, and should not be stored above 30 C (for tube packaging). The product is required to be kept out of the sight and reach of children.

Q: Can Bisolbruis be used at the same time as cold and flu relief products?

Caution is required with combination products, especially those that contain cough suppressants (antitussives). Official documents describe that co-administration with cough suppressants is generally avoided, as suppressing the cough reflex may cause the thinned mucus to build up in the airways.

Q: What is the role of the inactive ingredients in Bisolbruis?

The inactive ingredients are included in the formulation to enable the effervescent tablet to rapidly dissolve when mixed with water. This process is necessary for the medicine’s proper oral administration as an aqueous solution.

Q: Does Bisolbruis help with a sore throat, or just the cough?

The medicine’s primary purpose is to help relieve the difficulty associated with clearing thick, viscid secretions from the airways. This action relates to managing a productive cough.

Q: Are there specific patient groups where Bisolbruis is not recommended?

Use is officially contraindicated (should not be used) in children younger than two years of age, patients with known hypersensitivity to the ingredients, and individuals with active peptic ulceration.

Q: Does Bisolbruis lose its strength if it's past the expiration date?

To maintain stability, use of the medicine is limited to the expiration period printed on the package. Official guidelines state that after the tube is first opened, the product is required to be used within 10 or 20 days (depending on the container size).

Q: Why might Bisolbruis cause a runny nose or increased saliva in some people?

The medicine's mechanism of action is related to thinning mucus and secretions in the airways. A runny nose or increased saliva is not listed as a common or uncommon adverse reaction for the oral form in official documents.

Q: Can Bisolbruis be taken before bedtime?

Official instructions state the medicine should be taken after food. Official documents suggest that for patients with a reduced cough reflex, administration in the mornings is suggested.

How should Bisolbruis be stored and disposed of?

How to Store and Dispose of Bisolbruis?

The storage and disposal guidelines for Bisolbruis (Acetylcysteine effervescent tablets) are defined in regulatory documents to ensure product stability and safety. These requirements are mandatory.

Storage and Stability Requirements Disposal Requirements
Protect from moisture: Store in the original package. Do not dispose via wastewater or household waste.
Temperature constraint: Do not store above 30 C (for tube packaging). Ask a pharmacist for instructions on how to properly discard unused or expired medicine.
Child safety: Keep out of the sight and reach of children. Follow all local regulations for disposal.
In-use stability: Use within 10 or 20 days (depending on container size) after first opening the tube.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisolbruis found in:

A-Z Index: